NRAS

OC Oncoclínicas RJ

Others

Evaluation of neoantigens in patients with NRAS-mutated melanoma

 

Biomarker: BRAF and NRAS

Centro

OC Oncoclínicas RJ

Investigador principal

Andreia Cristina de Melo

Email

andreia.melo@medicos.oncoclinicas.com

Telefone

(21) 2127-0281/82

Critérios de inclusão

Confirmed histological diagnosis of cutaneous or mucosal melanoma, stage III or IV according to AJCC 8th edition, BRAF wild type.

Availability of tumor tissue for analysis (primary or metastatic samples) at any stage of your treatment.

Life expectancy of more than three months (according to the best medical judgment).

Patient must agree to have their clinical data collected anonymously and samples sent to a foreign laboratory (WIS)

Participant must agree to return to the site for additional peripheral blood collection, if necessary.

Critérios de exclusão

Medical, psychiatric, cognitive or other conditions that may compromise the ability to understand the information provided (to the patient), the ability to provide informed consent, and adherence to the study protocol.

BRAF mutated melanomas

Coordenador(es)

Tamires Almeida

Entre em contato

Telefone(s)

Email(s)

Compartilhe
Ou compartilhe o link
Link copiado para sua área de trabalho.